ANPEP and neoplasm: Given that HLA class I APM downregulation or loss is a known mechanism of immune evasion utilized by HNSCC (31), we explored the use of 5-aza to improve the tumor antigenicity of HNSCCs and improve clinical outcomes upon rechallenge with ICB therapy.